<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23936115</PMID><DateCompleted><Year>2014</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>7</Issue><PubDate><Year>2013</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Protective efficacy of VP1-specific neutralizing antibody associated with a reduction of viral load and pro-inflammatory cytokines in human SCARB2-transgenic mice.</ArticleTitle><Pagination><StartPage>e69858</StartPage><MedlinePgn>e69858</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e69858</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0069858</ELocationID><Abstract><AbstractText>Hand-foot-mouth diseases (HFMD) caused by enterovirus 71 (EV71) and coxsackievirus 16 (CVA16) in children have now become a severe public health issue in the Asian-Pacific region. Recently we have successfully developed transgenic mice expressing human scavenger receptor class B member 2 (hSCARB2, a receptor of EV71 and CVA16) as an animal model for evaluating the pathogenesis of enterovirus infections. In this study, hSCARB2-transgenic mice were used to investigate the efficacy conferred by a previously described EV71 neutralizing antibody, N3. A single injection of N3 effectively inhibited the HFMD-like skin scurfs in mice pre-infected with clinical isolate of EV71 E59 (B4 genotype) or prevented severe limb paralysis and death in mice pre-inoculated with 5746 (C2 genotype). This protection was correlated with remarkable reduction of viral loads in the brain, spinal cord and limb muscles. Accumulated viral loads and the associated pro-inflammatory cytokines were all reduced. The protective efficacy of N3 was not observed in animals challenged with CVA16. This could be due to dissimilarity sequences of the neutralizing epitope found in CVA16. These results indicate N3 could be useful in treating severe EV71 infections and the hSCARB2-transgenic mouse could be used to evaluate the protective efficacy of potential anti-enterovirus agent candidates.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Hsuen-Wen</ForeName><Initials>HW</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan town, Miaoli County, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Yi-Wen</ForeName><Initials>YW</Initials></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Hui-Min</ForeName><Initials>HM</Initials></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Min-Han</ForeName><Initials>MH</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Chia-Chyi</ForeName><Initials>CC</Initials></Author><Author ValidYN="Y"><LastName>Shao</LastName><ForeName>Hsiao-Yun</ForeName><Initials>HY</Initials></Author><Author ValidYN="Y"><LastName>Chong</LastName><ForeName>Pele</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Sia</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Chow</LastName><ForeName>Yen-Hung</ForeName><Initials>YH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>07</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036022">Capsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018836">Inflammation Mediators</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051907">Lysosomal Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051116">Receptors, Scavenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C074299">SCARB2 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000918" MajorTopicYN="N">Antibody Specificity</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036022" MajorTopicYN="N">Capsid Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003384" MajorTopicYN="N">Coxsackievirus Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003429" MajorTopicYN="N">Cross Reactions</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018836" MajorTopicYN="N">Inflammation Mediators</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051907" MajorTopicYN="N">Lysosomal Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051116" MajorTopicYN="N">Receptors, Scavenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="Y">Viral Load</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>4</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>6</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>7</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23936115</ArticleId><ArticleId IdType="pmc">PMC3728341</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0069858</ArticleId><ArticleId IdType="pii">PONE-D-13-14951</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pulli T, Koskimies P, Hyypia T (1995) Molecular comparison of coxsackie A virus serotypes. Virology 212: 30&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">7676647</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Alonso S, Chow VT, Poh CL (2007) Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect 9: 1299&#x2013;1306.</Citation><ArticleIdList><ArticleId IdType="pubmed">17890123</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang SW, Hsu YW, Smith DJ, Kiang D, Tsai HP, et al. (2009) Reemergence of enterovirus 71 in 2008 in taiwan: dynamics of genetic and antigenic evolution from 1998 to 2008. J Clin Microbiol 47: 3653&#x2013;3662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772620</ArticleId><ArticleId IdType="pubmed">19776232</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin TY, Twu SJ, Ho MS, Chang LY, Lee CY (2003) Enterovirus 71 outbreaks, Taiwan: occurrence and recognition. Emerg Infect Dis 9: 291&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2963902</ArticleId><ArticleId IdType="pubmed">12643822</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CN, Lin YC, Fann C, Liao NS, Shih SR, et al. (2001) Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 20: 895&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pubmed">11738755</ArticleId></ArticleIdList></Reference><Reference><Citation>Khong WX, Yan B, Yeo H, Tan EL, Lee JJ, et al... (2012) A non mouse-adapted Enterovirus 71 (EV71) strain exhibits neurotropism causing neurological manifestations in a novel mouse model of EV71 infection. J Virol.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3302383</ArticleId><ArticleId IdType="pubmed">22130542</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto I, Hagiwara A, Kodama H (1978) Neurovirulence in cynomolgus monkeys of enterovirus 71 isolated from a patient with hand, foot and mouth disease. Arch Virol 56: 257&#x2013;261.</Citation><ArticleIdList><ArticleId IdType="pubmed">205198</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YF, Chou CT, Lei HY, Liu CC, Wang SM, et al. (2004) A mouse-adapted enterovirus 71 strain causes neurological disease in mice after oral infection. J Virol 78: 7916&#x2013;7924.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC446098</ArticleId><ArticleId IdType="pubmed">15254164</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown BA, Oberste MS, Alexander JP Jr, Kennett ML, Pallansch MA (1999) Molecular epidemiology and evolution of enterovirus 71 strains isolated from 1970 to 1998. J Virol 73: 9969&#x2013;9975.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC113047</ArticleId><ArticleId IdType="pubmed">10559310</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu ML, Lee YP, Wang YF, Lei HY, Liu CC, et al. (2005) Type I interferons protect mice against enterovirus 71 infection. J Gen Virol 86: 3263&#x2013;3269.</Citation><ArticleIdList><ArticleId IdType="pubmed">16298971</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YW, Yu SL, Shao HY, Lin HY, Liu CC, et al. (2013) Human SCARB2 Transgenic Mice as an Infectious Animal Model for Enterovirus 71. PLoS One 8: e57591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3581494</ArticleId><ArticleId IdType="pubmed">23451246</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S, Yamashita Y, Li J, Hanagata N, Minowa T, et al. (2009) Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med 15: 798&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pubmed">19543282</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SM, Lei HY, Huang KJ, Wu JM, Wang JR, et al. (2003) Pathogenesis of enterovirus 71 brainstem encephalitis in pediatric patients: roles of cytokines and cellular immune activation in patients with pulmonary edema. J Infect Dis 188: 564&#x2013;570.</Citation><ArticleIdList><ArticleId IdType="pubmed">12898444</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin TY, Chang LY, Huang YC, Hsu KH, Chiu CH, et al. (2002) Different proinflammatory reactions in fatal and non-fatal enterovirus 71 infections: implications for early recognition and therapy. Acta Paediatr 91: 632&#x2013;635.</Citation><ArticleIdList><ArticleId IdType="pubmed">12162592</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin TY, Hsia SH, Huang YC, Wu CT, Chang LY (2003) Proinflammatory cytokine reactions in enterovirus 71 infections of the central nervous system. Clin Infect Dis 36: 269&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">12539066</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SM, Liu CC, Tseng HW, Wang JR, Huang CC, et al. (1999) Clinical spectrum of enterovirus 71 infection in children in southern Taiwan, with an emphasis on neurological complications. Clin Infect Dis 29: 184&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">10433583</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang HW, Liu CC, Lin MH, Ho HM, Yang YT, et al. (2011) Generation of murine monoclonal antibodies which cross-neutralize human enterovirus genogroup B isolates. J Virol Methods 173: 189&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">21315763</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YW, Lin HY, Tsou YL, Chitra E, Hsiao KN, et al. (2012) Human SCARB2-mediated entry and endocytosis of EV71. PLoS One 7: e30507.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3260287</ArticleId><ArticleId IdType="pubmed">22272359</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SM, Lei HY, Yu CK, Wang JR, Su IJ, et al. (2008) Acute chemokine response in the blood and cerebrospinal fluid of children with enterovirus 71-associated brainstem encephalitis. J Infect Dis 198: 1002&#x2013;1006.</Citation><ArticleIdList><ArticleId IdType="pubmed">18710325</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SM, Lei HY, Huang MC, Su LY, Lin HC, et al. (2006) Modulation of cytokine production by intravenous immunoglobulin in patients with enterovirus 71-associated brainstem encephalitis. J Clin Virol 37: 47&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">16861032</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Huang X, Ku Z, Wang T, Liu F, et al. (2012) Characterization of enterovirus 71 capsids using subunit protein-specific polyclonal antibodies. J Virol Methods 187: 127&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">23046991</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Ku Z, Cai Y, Sun B, Leng Q, et al. (2011) Detection, characterization and quantitation of coxsackievirus A16 using polyclonal antibodies against recombinant capsid subunit proteins. J Virol Methods 173: 115&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">21295614</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YC, Yu CK, Wang YF, Liu CC, Su IJ, et al. (2004) A murine oral enterovirus 71 infection model with central nervous system involvement. J Gen Virol 85: 69&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">14718621</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagata N, Iwasaki T, Ami Y, Tano Y, Harashima A, et al. (2004) Differential localization of neurons susceptible to enterovirus 71 and poliovirus type 1 in the central nervous system of cynomolgus monkeys after intravenous inoculation. J Gen Virol 85: 2981&#x2013;2989.</Citation><ArticleIdList><ArticleId IdType="pubmed">15448361</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong KC, Badmanathan M, Devi S, Leong KL, Cardosa MJ, et al. (2008) Pathologic characterization of a murine model of human enterovirus 71 encephalomyelitis. J Neuropathol Exp Neurol 67: 532&#x2013;542.</Citation><ArticleIdList><ArticleId IdType="pubmed">18520772</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura-Kuroda J, Yasui K (1988) Protection of mice against Japanese encephalitis virus by passive administration with monoclonal antibodies. J Immunol 141: 3606&#x2013;3610.</Citation><ArticleIdList><ArticleId IdType="pubmed">2460542</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang YC, Lin TY, Lin YJ, Lien RI, Chou YH (2001) Prophylaxis of intravenous immunoglobulin and acyclovir in perinatal varicella. Eur J Pediatr 160: 91&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">11271397</ArticleId></ArticleIdList></Reference><Reference><Citation>Geller TJ, Condie D (1995) A case of protracted coxsackie virus meningoencephalitis in a marginally immunodeficient child treated successfully with intravenous immunoglobulin. J Neurol Sci 129: 131&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">7608726</ArticleId></ArticleIdList></Reference><Reference><Citation>Komatsu H, Shimizu Y, Takeuchi Y, Ishiko H, Takada H (1999) Outbreak of severe neurologic involvement associated with Enterovirus 71 infection. Pediatr Neurol 20: 17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">10029254</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, et al. (1999) An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med 341: 929&#x2013;935.</Citation><ArticleIdList><ArticleId IdType="pubmed">10498487</ArticleId></ArticleIdList></Reference><Reference><Citation>Lum LC, Wong KT, Lam SK, Chua KB, Goh AY, et al. (1998) Fatal enterovirus 71 encephalomyelitis. J Pediatr 133: 795&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pubmed">9842048</ArticleId></ArticleIdList></Reference><Reference><Citation>Khong WX, Foo DG, Trasti SL, Tan EL, Alonso S (2011) Sustained high levels of interleukin-6 contribute to the pathogenesis of enterovirus 71 in a neonate mouse model. J Virol 85: 3067&#x2013;3076.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3067852</ArticleId><ArticleId IdType="pubmed">21228224</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn P, Stratov I, Nagarajan L, Davis S (2001) Neurological manifestations of enterovirus 71 infection in children during an outbreak of hand, foot, and mouth disease in Western Australia. Clin Infect Dis 32: 236&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">11170913</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan J, Liu Z, Lim T, Zhang H, He J, et al. (2009) CXCL10 inhibits viral replication through recruitment of natural killer cells in coxsackievirus B3-induced myocarditis. Circ Res 104: 628&#x2013;638.</Citation><ArticleIdList><ArticleId IdType="pubmed">19168435</ArticleId></ArticleIdList></Reference><Reference><Citation>Yajima T (2011) Viral myocarditis: potential defense mechanisms within the cardiomyocyte against virus infection. Future Microbiol 6: 551&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3131135</ArticleId><ArticleId IdType="pubmed">21585262</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergmann CC, Lane TE, Stohlman SA (2006) Coronavirus infection of the central nervous system: host-virus stand-off. Nat Rev Microbiol 4: 121&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7096820</ArticleId><ArticleId IdType="pubmed">16415928</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou AH, Liu CC, Chang JY, Lien SP, Guo MS, et al. (2012) Immunological evaluation and comparison of different EV71 vaccine candidates. Clin Dev Immunol 2012: 831282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3447357</ArticleId><ArticleId IdType="pubmed">23008736</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia CS, Liu JN, Li WB, Ma CM, Lin SZ, et al. (2010) The cross-reactivity of the enterovirus 71 to human brain tissue and identification of the cross-reactivity related fragments. Virol J 7: 47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2839975</ArticleId><ArticleId IdType="pubmed">20170551</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunt AR, Frederickson S, Hinkel C, Bowdish KS, Roehrig JT (2006) A humanized murine monoclonal antibody protects mice either before or after challenge with virulent Venezuelan equine encephalomyelitis virus. J Gen Virol 87: 2467&#x2013;2476.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894184</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuller H, Del Mar C (2006) Immunoglobulin treatment for respiratory syncytial virus infection. Cochrane Database Syst Rev: CD004883.</Citation><ArticleIdList><ArticleId IdType="pubmed">17054220</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu SC, Liu CC, Lian WC (2004) Optimization of microcarrier cell culture process for the inactivated enterovirus type 71 vaccine development. Vaccine 22: 3858&#x2013;3864.</Citation><ArticleIdList><ArticleId IdType="pubmed">15364432</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Lian WC, Butler M, Wu SC (2007) High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell culture. Vaccine 25: 19&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">16919374</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng J, Dubreuil P, Pillot J (1997) A new PCR-based seroneutralization assay in cell culture for diagnosis of hepatitis E. J Clin Microbiol. 35: 1373&#x2013;1377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC229751</ArticleId><ArticleId IdType="pubmed">9163446</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>